This September, SpiroChem will participate in four international conferences bringing together experts across medicinal chemistry, drug discovery, biotechnology and life sciences partnering.
The team will be present at the following meetings:
EFMC International Symposium on Medicinal Chemistry 2026
September 06–10, 2026 | Basel, Switzerland
Bringing together the European medicinal chemistry and chemical biology community, EFMC Medicinal Chemistry 2026 is a key symposium for scientists and industry experts working across medicinal chemistry and drug discovery. It will feature plenary sessions and three parallel tracks covering selected topics, emerging research and developments across the field.
Attending for SpiroChem:
Thomas Fessard, PhD – CEO
Gerhard Mueller, PhD – CSO
Florent Beaufils, PhD – COO
Laurence Jung, PhD – Innovative Solutions Developer
14th International Symposium on DNA-Encoded Chemical Libraries
September 10–11, 2026 | Zurich, Switzerland
Held at ETH Zurich, the symposium will bring together scientists and industry experts working on DNA-encoded chemical libraries and their applications in pharmaceutical research and drug discovery. The program will address recent developments in DEL technology, hit identification and emerging approaches across the field.
Attending for SpiroChem:
Florent Beaufils, PhD – COO
Davide Deodato, PhD – Research Chemist & MedChem Project Leader
RESI Boston 2026
September 22–23, 2026 | Boston, United States
Taking place as part of Biotech Week Boston, RESI brings together early-stage life science companies, investors, corporate partners and business development professionals. The conference provides a dedicated environment for partnering, fundraising discussions and strategic connections across the biotech and healthcare ecosystem..
Attending for SpiroChem:
Thomas Fessard, PhD – CEO
Discovery on Target 2026
September 28–October 1, 2026 | Boston, United States
Discovery on Target brings together the scientific and technology communities advancing drug discovery. The program covers areas including target identification, lead generation, screening technologies, AI/ML, small molecules, peptides and emerging therapeutic modalities.
Attending for SpiroChem:
Thomas Fessard, PhD – CEO
Across these meetings, SpiroChem will engage with scientists, biotech companies, industry partners and other stakeholders to exchange perspectives on current developments in drug discovery and explore new opportunities for collaboration.
